Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course - Wikidata - awgldk - TriplyDB

Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

http://www.wikidata.org/entity/Q34253776

about

Update on advances in molecular PET in urological oncology Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors.Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.Use of three-dimensional time-resolved phase-contrast magnetic resonance imaging with vastly undersampled isotropic projection reconstruction to assess renal blood flow in a renal cell carcinoma patient treated with sunitinib: a case report Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Vascularity of primary and metastatic renal cell carcinoma specimens.The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.The role of functional imaging in the era of targeted therapy of renal cell carcinoma.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Metabolic reprogramming in clear cell renal cell carcinoma.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.

P2860

Q33625389-1AA9C25B-8E2D-47FD-89A7-CAF6CD1B0322 Q33755947-E5549BD7-4B12-4AD9-AA7A-2479FEFA6939 Q33760493-78DCFD37-78EF-48BE-B945-EF087E158847 Q33780956-152BFEA5-B377-4F15-AFFD-EA0E6375F160 Q33792683-3F07B3BD-79C6-4F67-A313-75D2113CFD1E Q33843677-63FB5A7A-09F8-488E-BC1C-E8D32085BB89 Q33946316-9991BF5C-28F4-431A-94E7-3F1309090B2C Q34067451-462FFFAC-7B20-44D4-A7AC-E83CCE4C9305 Q34990800-A43B612D-0DA6-4E89-B69E-006625027FD8 Q35169825-F65C3B5B-BC3B-4ED8-B89B-59C08A63F446 Q35793080-7B8D5FBD-B69D-4DD8-8301-708038323FA6 Q35917780-850930B1-8463-467B-AC0E-5CCF8477E2E7 Q36001780-BE8EB342-433B-4E59-A105-5AC31827E805 Q36429759-0E64F3D4-D21A-448C-8DB8-5BDEAADED875 Q36567385-3D006855-B354-49DF-BAD7-BCD652584CBF Q36578610-1EAD3D69-CD68-4CEC-903B-0F42D6E23548 Q37576212-56C28509-8D9C-4545-809C-E82F7598791B Q38099238-3DA68C1B-E018-46AB-B45F-67F9501BBDF8 Q38196855-FE815691-B011-49DA-BAAF-648D84AEAF5B Q39290307-7ACDA38D-70DA-428A-B4C4-F42F19320B03 Q41660750-0FF69C74-3EA4-4777-B2FE-FF13D2106805 Q49165684-B97DAFBD-2352-48A5-A9DE-F0614D825C7F Q52780316-09A1E9A5-5E94-40D7-96BD-F265EE21BC22 Q52877176-D3C54FF4-ED6E-4F95-8E11-F4C9F4EDB699

P2860

Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

http://www.wikidata.org/entity/Q34253776

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Early assessment by FDG-PET/CT ...... s predictive of disease course

@ast

Early assessment by FDG-PET/CT ...... s predictive of disease course

@en

Early assessment by FDG-PET/CT ...... s predictive of disease course

@nl

type

label

Early assessment by FDG-PET/CT ...... s predictive of disease course

@ast

Early assessment by FDG-PET/CT ...... s predictive of disease course

@en

Early assessment by FDG-PET/CT ...... s predictive of disease course

@nl

prefLabel

Early assessment by FDG-PET/CT ...... s predictive of disease course

@ast

Early assessment by FDG-PET/CT ...... s predictive of disease course

@en

Early assessment by FDG-PET/CT ...... s predictive of disease course

@nl

P1433

Q34253776-8B481D1B-67B9-4B29-8CBC-300CC1F1CC40

P1476

Q34253776-AE6620D1-3DFE-41CE-A9FF-D0D4A4D7C12F

P2093

Q34253776-0235B8D7-D5FA-4BAD-BCBF-68C3348FD4C8

Q34253776-13B52DA7-FEEB-4155-AB80-B02C636587D8

Q34253776-1BB1F5A4-44D2-4721-A822-F7423A90D7BC

Q34253776-2EEF682D-3A5E-45E0-9B88-6B9A7AED9DFD

Q34253776-51BF6AA5-4043-48A4-98A3-85598516F4F5

Q34253776-5A0C1FD9-7B04-4A96-857A-926659C7F3B7

Q34253776-7B3B60DD-03EB-48D7-8419-247A7C75E6C0

Q34253776-7FA9BCD7-CA17-45D7-9005-6EB24CB8466D

Q34253776-A31137F1-4398-46A8-ACD7-B10650D4EA21

Q34253776-A6BCE8AB-2014-472E-BDB2-A1DC523942B9

P2860

Q34253776-16F6B1B1-EB5B-4283-B81C-0B2FFA393F24

Q34253776-3064C2B9-1938-49CA-817A-9980EEA1BD78

Q34253776-34D07126-CCA7-40CC-BEB4-0D675C4146C8

Q34253776-3C10AA17-A023-4EF5-846A-B588352C9D0B

Q34253776-52573A63-4EDA-4E45-8CC9-01DD2E14146B

Q34253776-55767B01-5217-4DF7-BCB5-2BF69D264C69

Q34253776-58916395-8657-4DA6-99C1-25F634DF8107

Q34253776-5A866657-B210-4CF9-ACB2-255255AA6671

Q34253776-6AD318BD-3FCE-417D-81CA-FAECF027694F

Q34253776-7DBBE7E3-EC00-4B69-8C8E-468D492D16C3

P2888

Q34253776-6A3DA16B-C8E1-42F9-AD61-C88C9D572D72

P304

Q34253776-F73A5E1D-33FC-4DA2-A706-345364B71547

P31

Q34253776-05706939-E561-41DC-BAB7-232AABBBFD1A

P356

Q34253776-F184B337-E877-416B-AA6F-20E2E2282B85

P407

Q34253776-7FF386BB-FA03-46C5-8500-ADEE6B6D6C6D

P478

Q34253776-1D6E5596-D353-432E-A9D3-DE37A22BADF9

P577

Q34253776-675C5CEA-5728-46E3-9F43-8276E4D1BD5B

P5875

Q34253776-A8584071-18FC-4D3B-8512-DE5BF2766C8F

P6179

Q34253776-E25C42EB-8668-4998-89C6-CE078CDA7B1C

P698

Q34253776-41F29C5C-C0B9-4982-A6EA-24CDB193F467

P932

Q34253776-D7E8D968-923E-46A9-A92F-35E9388B6BF9

P356

1471-2407-12-162

P1433

P1476

Early assessment by FDG-PET/CT ...... s predictive of disease course

@en

P2093

Daiki Ueno

http://www.w3.org/2001/XMLSchema#string

Futoshi Sano

http://www.w3.org/2001/XMLSchema#string

Ichiro Ikeda

http://www.w3.org/2001/XMLSchema#string

Kazuhide Makiyama

http://www.w3.org/2001/XMLSchema#string

Kazuki Kobayashi

http://www.w3.org/2001/XMLSchema#string

Masahiro Yao

http://www.w3.org/2001/XMLSchema#string

Narihiko Hayashi

http://www.w3.org/2001/XMLSchema#string

Noboru Nakaigawa

http://www.w3.org/2001/XMLSchema#string

Ryogo Minamimoto

http://www.w3.org/2001/XMLSchema#string

Sumio Noguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Renal-cell carcinoma.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.

P2888

1471-2407-12-162

P304

162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-162

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224887232

http://www.w3.org/2001/XMLSchema#string

P6179

1039196465

http://www.w3.org/2001/XMLSchema#string

P698

22551397

http://www.w3.org/2001/XMLSchema#string

P932

3418566

http://www.w3.org/2001/XMLSchema#string